Abivax Confirms Trading Resumption
Paris, May 2nd, 2017 at 7:00am CEST - ABIVAX (Euronext Paris: FR0012333284 - ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, confirms the resumption of trading effective as of Euronext Paris market opening at 9:00am CEST.
As a reminder, trading was suspended, as requested by the company and in agreement with the AMF (French Market Authority), on Friday April, 28th 2017 at 11:29am (CEST).
The company will also disclose top line results of ABX464-004, the 2nd Phase IIa of ABX464, its lead drug candidate in the treatment of HIV, today before market opening.
About ABIVAX (www.abivax.com)
ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease. To do this ABIVAX leverages three technology platforms for drug discovery: antiviral, immune enhancing and polyclonal antibodies. ABX464, its most advanced compound, is currently in Phase II clinical trials to test its ability to enable a functional cure for patients with HIV/AIDS. It is a first-in-class oral small antiviral molecule which blocks HIV replication through a unique mechanism of action and, separately, also has a strong anti-inflammatory effect. In addition, ABIVAX is advancing a clinical stage immune enhancer as well as multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue); several of these compounds are planned to enter clinical development within the next 18 months. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX).
More information on the company is available at www.abivax.com.
Follow us on Twitter @ABIVAX_
As a reminder, trading was suspended, as requested by the company and in agreement with the AMF (French Market Authority), on Friday April, 28th 2017 at 11:29am (CEST).
The company will also disclose top line results of ABX464-004, the 2nd Phase IIa of ABX464, its lead drug candidate in the treatment of HIV, today before market opening.
About ABIVAX (www.abivax.com)
ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease. To do this ABIVAX leverages three technology platforms for drug discovery: antiviral, immune enhancing and polyclonal antibodies. ABX464, its most advanced compound, is currently in Phase II clinical trials to test its ability to enable a functional cure for patients with HIV/AIDS. It is a first-in-class oral small antiviral molecule which blocks HIV replication through a unique mechanism of action and, separately, also has a strong anti-inflammatory effect. In addition, ABIVAX is advancing a clinical stage immune enhancer as well as multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue); several of these compounds are planned to enter clinical development within the next 18 months. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX).
More information on the company is available at www.abivax.com.
Follow us on Twitter @ABIVAX_